- Presentation highlights EVO301’s clear therapeutic signal, favorable safety and tolerability profile, and reinforces IL-18 inhibition as a novel, clinically relevant approach to treating atopic dermatitis
- Biomarker analyses confirm robust Th2 pathway modulation, as well as broad anti-inflammatory activity across multiple inflammatory pathways (Th1, Th17/22)
- Plan to initiate subcutaneous Phase 2b dose-ranging trial in mid-2027
Evommune, Inc. (NYSE:EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today shared additional data from its Phase 2a proof-of-concept trial of EVO301 in adults with moderate-to-severe atopic dermatitis (AD) during a late-breaking oral presentation at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna, Austria. EVO301 is a long-acting injectable fusion protein designed to selectively inhibit overactive IL-18, with the potential to offer broader upstream pathway control than standard-of-care biologics.
The 70-patient trial was designed to evaluate the safety and efficacy of intravenous dosing of 5mg/kg at Baseline and Week 4 (n=48 active, n=22 placebo) with a primary endpoint at Week 12, 8 weeks after the last dose. EVO301 demonstrated a clear therapeutic signal, achieving activity at Week 12 comparable to dose-optimized marketed biologics at Week 16, along with a favorable safety and tolerability profile. In addition, IL-18 inhibition was validated as a novel AD target, with biomarker analyses confirming robust target engagement and broad anti-inflammatory activity across the Th2, Th1, Th17, and Th22 pathways.